A jury has found that a vitamin C manufacturer based in China, as well as its affiliate company, are guilty of price-fixing in the US and have been ordered to pay $162 million. The $54.1 million in damages to the victims of the class action suit were trebled for Hebei Welcome Pharmaceutical Co Ltc, the vitamin C manufacturer. Sources say that the two defendants who were previously part of the case settled out of court for a reported $22.5 million. As CPI previously reported, the defendants had used a rare defense claiming that their company forced them to fix prices abroad, a defense known as the foreign sovereign compulsion doctrine.
Featured News
FTC Warns Patent-Right Acquisitions Cannot Escape Antitrust Review in Amgen Enbrel Case
Aug 24, 2026 by
CPI
nVent Bets $1.75 Billion on Data-Center Power Demand
Aug 24, 2026 by
CPI
Squire Patton Boggs Adds Former FTC Antitrust Lawyer
Aug 24, 2026 by
CPI
Tacoma Sues Fire-Truck Makers in Expanding US Antitrust Fight
Aug 24, 2026 by
CPI
California Breaks Off Paramount Talks Over $110 Billion Warner Bros. Deal
Aug 24, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Antipasto
Aug 24, 2026 by
CPI
“Anti-Monopoly” Antitrust Enforcement: Lessons Learned from the Biden Administration
Aug 24, 2026 by
Diana L. Moss
FTC v. Meta: The Importance of Quantitative Evidence in Antitrust
Aug 24, 2026 by
Dennis Carlton, John A. List, Allan Shampine, Hal Sider & Theresa Sullivan
Competitor Information Exchanges: Reducing Market Uncertainty Is What Matters, Not Level Of Detail
Aug 24, 2026 by
Kasia Czapracka, Assimakis Komninos, James Killick & Nina Frie
When Politics Meets Merger Control: 10 Transatlantic Takeaways
Aug 24, 2026 by
Rachel Brandenburger